Cellular Response to Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions*

The extracellular matrix plays an important role in growth factor biology, serving as a potential platform for rapid growth factor mobilization or a sink for concentrated sequestration. We now demonstrate that when a growth factor binds reversibly to the matrix, its effects are augmented by this interaction, and when the factor is absorbed irreversibly to the extracellular matrix, it becomes sequestered. These findings call into question the notion that all growth factors are best presented to cells and tissues in a sustained and controlled fashion. In our studies, we examined basic fibroblast growth factor (bFGF) and transforming growth factor-β1 (TGF-β1) release kinetics from synthetically fabricated microsphere devices and naturally synthesized extracellular matrix. While the sustained release of bFGF was up to 3.0-fold more potent at increasing vascular endothelial and smooth muscle cell proliferation than bolus administration, the reverse was true for TGF-β1. A bolus of TGF-β1 inhibited vascular cells up to 3.8-fold more efficiently than the same amount of TGF-β1 if control-released. Both growth factors bound to the extracellular matrix, but only bFGF was released in a controlled fashion (2.8%/day). Contact with the extracellular matrix and subsequent release enhanced bFGF activity such that it was 86% more effective at increasing smooth muscle cell numbers than equal amounts of growth factor diluted from frozen stock. TGF-β1 remained tightly adherent. The small amount of TGF-β1 released from the extracellular matrix was ∼30% less effective than bolus administration at inhibiting vascular endothelial and smooth muscle cell growth. Sustained growth factor release may be the preferable mode of administration, but only when a similar mode of metabolism is utilized endogenously.

[1]  D. Lauffenburger,et al.  Receptor‐mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor α , 1996, Journal of cellular physiology.

[2]  A. Cuello,et al.  Microencapsulated nerve growth factor: Effects on the forebrain neurons following devascularizing cortical lesions , 1992, Neuroscience Letters.

[3]  D. Rifkin,et al.  Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor , 1990, The Journal of cell biology.

[4]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[5]  P Aebischer,et al.  Basic fibroblast growth factor released from synthetic guidance channels facilitates peripheral nerve regeneration across long nerve gaps , 1989, Journal of neuroscience research.

[6]  J. Davidson,et al.  Modulation of transforming growth factor‐beta 1 stimulated elastin and collagen production and proliferation in porcine vascular smooth muscle cells and skin fibroblasts by basic fibroblast growth factor, transforming growth factor‐α, and insulin‐like growth factor‐I , 1993 .

[7]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[8]  D. Moscatelli,et al.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells , 1987, The Journal of cell biology.

[9]  D. Lauffenburger,et al.  Proliferative Response of Fibroblasts Expressing Internalization‐Deficient Epidermal Growth Factor (EGF) Receptors Is Altered via Differential EGF Depletion Effect , 1994, Biotechnology progress.

[10]  C. M. Park,et al.  Induction of retinal regeneration in vivo by growth factors. , 1991, Developmental biology.

[11]  M. Sakuda,et al.  Stimulation of cartilage‐matrix proteoglycan synthesis by morphologically transformed chondrocytes grown in the presence of fibroblast growth factor and transforming growth factor‐beta , 1989, Journal of cellular physiology.

[12]  J. Dasch,et al.  Capture Immunoassays Specific for TGFβ1 and TGFβ2: Use in Pharmacokinetic Studies , 1990 .

[13]  W. Stell,et al.  Basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta) act as stop and go signals to modulate postnatal ocular growth in the chick. , 1994, Experimental eye research.

[14]  J. Reynolds,et al.  Bone-derived growth factor release from poly(α-hydroxy acid) implants in vitro , 1993 .

[15]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[16]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[17]  J. McPherson,et al.  Exogenous transforming growth factor-beta 2 enhances connective tissue formation and wound strength in guinea pig dermal wounds healing by secondary intent. , 1990, Annals of surgery.

[18]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.

[19]  B. Nies,et al.  Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics. , 1994, Biomaterials.

[20]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[21]  William E. Russell,et al.  Pharmacokinetics of TGFβ with Emphasis on Effects in Liver and Gut , 1990 .

[22]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[23]  C. Mitchell,et al.  bFGF enhances the development of the collateral circulation after acute arterial occlusion. , 1992, Biochemical and biophysical research communications.

[24]  G. Koh,et al.  Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. , 1995, The Journal of clinical investigation.

[25]  K. Uekama,et al.  Aluminium β‐Cyclodextrin Sulphate as a Stabilizer and Sustained‐release Carrier for Basic Fibroblast Growth Factor , 1994 .

[26]  J. Massagué,et al.  Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. , 1985, The Journal of biological chemistry.

[27]  T J Ebner,et al.  Sustained release of nerve growth factor from biodegradable polymer microspheres. , 1992, Neurosurgery.

[28]  M. Kirschner,et al.  Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early xenopus embryo , 1987, Cell.

[29]  W. Heath,et al.  Mutations in the heparin-binding domains of human basic fibroblast growth factor alter its biological activity. , 1991, Biochemistry.

[30]  T. Nabeshima,et al.  Sustained release of basic fibroblast growth factor from the synthetic vascular prosthesis using hydroxypropylchitosan acetate. , 1995, Journal of biomedical materials research.

[31]  A. Hoffman,et al.  Novel delivery system for inducing quiescence in intestinal stem cells in rats by transforming growth factor beta 1. , 1994, Gastroenterology.

[32]  E. Edelman,et al.  Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. , 1992, Biochemistry.

[33]  W. Mark Saltzman,et al.  Distribution of nerve growth factor following direct delivery to brain interstitium , 1995, Brain Research.

[34]  P. Aebischer,et al.  NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion , 1990, Experimental Neurology.

[35]  J. Folkman,et al.  Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. White,et al.  Acceleration of tensile strength of incisions treated with EGF and TGF-beta. , 1988, Annals of surgery.

[37]  M. Sporn,et al.  Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. , 1987, Science.

[38]  London P. Cuatrecasas Peptide Growth Factors and Their Receptors I , 1990, Handbook of Experimental Pharmacology.

[39]  B. Olwin,et al.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation , 1991, Science.

[40]  M. Klagsbrun,et al.  Extracellular matrix‐resident basic fibroblast growth factor: Implication for the control of angiogenesis , 1991, Journal of cellular biochemistry.

[41]  P. Dell’Era,et al.  Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. , 1991, Cell regulation.

[42]  W. Saltzman,et al.  Controlled release of nerve growth factor from a polymeric implant , 1990, Brain Research.

[43]  E. Edelman,et al.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Vukicevic,et al.  Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. , 1991, Developmental biology.

[45]  C. Daniel,et al.  Reversible inhibition of mammary gland growth by transforming growth factor-beta. , 1987, Science.

[46]  J. Folkman,et al.  Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. , 1989, Biochemistry.

[47]  M. Klagsbrun,et al.  Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells , 1989, The Journal of cell biology.

[48]  D. Rifkin,et al.  Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long‐term stimulation of plasminogen activator production and DNA synthesis , 1989, Journal of cellular physiology.

[49]  K. Alitalo,et al.  Enhanced bFGF gene expression in response to transforming growth factor-beta stimulation of AKR-2B cells. , 1993, Growth factors.

[50]  E. Edelman,et al.  Controlled Release of Fibroblast Growth Factor: Activity in Cell Culture , 1991 .

[51]  A. Ammann,et al.  Recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) enhances healing and strength of granulation skin wounds. , 1990, Growth factors.

[52]  M. Rusnati,et al.  Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form , 1989, Journal of cellular physiology.

[53]  M. J. Hickey,et al.  An improved matrix-type controlled release system for basic fibroblast growth factor. , 1994, Biochemical and biophysical research communications.

[54]  M. White,et al.  Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. , 1987, Science.

[55]  D. Gospodarowicz,et al.  Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor beta. , 1988, Endocrinology.

[56]  E. Edelman,et al.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. , 1992, The Journal of clinical investigation.

[57]  J. Ranchalis,et al.  Controlled release of TGF-β1 from a biodegradable matrix for bone regeneration , 1994 .

[58]  G. D. Phillips,et al.  Angiogenic Activity in Damaged Skeletal Muscle , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[59]  D. Gospodarowicz,et al.  Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic , 1980, Cell.

[60]  D. Hill,et al.  Bioavailability: is this a key event in regulating the actions of peptide growth factors? , 1992, The Journal of endocrinology.

[61]  A. Baird,et al.  Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. , 1986, Biochemical and biophysical research communications.

[62]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[63]  H. Herschman,et al.  Epidermal growth factor. Relationship between receptor regulation and mitogenesis in 3T3 cells. , 1978, The Journal of biological chemistry.

[64]  Anita B. Roberts,et al.  Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.

[65]  D. Mcclure,et al.  Fibronectin‐associated transforming growth factor , 1987, Journal of cellular physiology.

[66]  W. Horton,et al.  Transforming growth factor‐beta and fibroblast growth factor act synergistically to inhibit collagen II synthesis through a mechanism involving regulatory DNA sequences , 1989, Journal of cellular physiology.

[67]  Y. Ito,et al.  Cell growth on immobilized cell growth factor. I. Acceleration of the growth of fibroblast cells on insulin-immobilized polymer matrix in culture medium without serum. , 1992, Biomaterials.

[68]  Wayne R. Gombotz,et al.  The Enhancement in Wound Healing by Transforming Growth Factor-β1 (TGF-β1) Depends on the Topical Delivery System , 1995 .

[69]  C. Gajdusek,et al.  Basic fibroblast growth factor and transforming growth factor beta‐1: Synergistic mediators of angiogenesis in vitro , 1993, Journal of cellular physiology.

[70]  A. Ammann,et al.  An intraosseous device for studies of bone-healing. The effect of transforming growth-factor beta. , 1992, The Journal of bone and joint surgery. American volume.

[71]  D. Moscatelli Metabolism of receptor-bound and matrix-bound basic fibroblast growth factor by bovine capillary endothelial cells , 1988, The Journal of cell biology.

[72]  A. Baird,et al.  Distribution of basic fibroblast growth factor in the 18-day rat fetus: localization in the basement membranes of diverse tissues , 1990, The Journal of cell biology.

[73]  D. Gospodarowicz,et al.  The angiogenic activity of the fibroblast and epidermal growth factor. , 1979, Experimental eye research.

[74]  D. Ingber,et al.  A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. , 1988, The American journal of pathology.

[75]  D. Rifkin,et al.  Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan , 1989, Journal of cellular physiology.

[76]  R. Langer,et al.  Ethylene-vinyl acetate copolymer microspheres for controlled release of macromolecules. , 1984, Journal of pharmaceutical sciences.

[77]  B. Spargo,et al.  Controlled release of transforming growth factor-β from lipid-based microcylinders , 1995 .

[78]  W. Shaw,et al.  In vitro slow release profile of endothelial cell growth factor immobilized within calcium alginate microbeads. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[79]  P. Speight,et al.  Effect of poly DL-lactide--co-glycolide implants and xenogeneic bone matrix-derived growth factors on calvarial bone repair in the rabbit. , 1994, Biomaterials.

[80]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[81]  L. Orci,et al.  Biphasic Effect of Transforming Growth Factor-β1 on in Vitro Angiogenesis , 1993 .

[82]  E. Edelman,et al.  Transforming growth factor beta 1 stimulates the production of basic fibroblast growth factor binding proteoglycans in Balb/c3T3 cells. , 1992, The Journal of biological chemistry.

[83]  R. Friesel,et al.  Long term growth factor exposure and differential tyrosine phosphorylation are required for DNA synthesis in BALB/c 3T3 cells. , 1993, The Journal of biological chemistry.

[84]  R Langer,et al.  Controlled and modulated release of basic fibroblast growth factor. , 1991, Biomaterials.

[85]  E. Edelman,et al.  Tissue engineered perivascular endothelial cell implants regulate vascular injury. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Moses,et al.  Biocompatible controlled release polymers for delivery of polypeptides and growth factors , 1991, Journal of cellular biochemistry.